Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amdipharm Mercury launches hypertension drug Nicardipine in UK
The drug has already been used in hospitals in Europe for some time and this will be the first introduction of the injection, licensed for use in the
The drug has already been used in hospitals in Europe for some time and this will be the first introduction of the injection, licensed for use in the
As part of the deal, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies. These therapies include T-cells activated against Epstein
The FDA fast track status helps in expediting the review and development of drugs which treat a serious or life-threatening condition and fill an unmet medical need. According
P. aeruginosa is a highly drug-resistant bacterial pathogen that causes serious disease in hospitalized patients. MEDI3902 is a new mAb engineered to combine three distinct mechanisms of action
More than 125 million people worldwide are affected by psoriasis, a chronic inflammatory disease of the skin resulting from an uncontrolled immune response. The FDA approval was primarily
Zestra is a topical treatment for female sexual desire disorder (FSDD), EjectDelay is indicated for premature ejaculation, Sensum+ is used to increase penile sensitivity, while Zestra Glide is
Blinatumomab, the first of the BiTE antibody constructs, is indicated to treat adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the
Onychomycosis is a fungal infection of the nail and nail bed that affects around 35 million people in the US. In July, Anacor entered into an exclusive agreement
The company’s French subsidiary TFChem has now moved into the next phase of the agreement with France-based contract research organization (CRO) Biogalenys to carry out the trials. Funding
MIN-202 is being developed by Minerva Neurosciences in collaboration with Janssen Pharmaceutica and Janssen Research & Development. The completion of the IND review will allow Janssen to start